Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDSpringWorks Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 4 | -$1.09 | -$0.49 | -$0.80 |
| Q2 2025 | 1 | -$0.80 | -$0.80 | -$0.80 |
| Q3 2025 | 1 | -$0.71 | -$0.71 | -$0.71 |
| Q4 2025 | 1 | -$0.55 | -$0.55 | -$0.55 |
| Q1 2026 | 1 | -$0.41 | -$0.41 | -$0.41 |
| Q2 2026 | 1 | -$0.21 | -$0.21 | -$0.21 |
| Q3 2026 | 1 | -$0.02 | -$0.02 | -$0.02 |
| Q4 2026 | 1 | $0.16 | $0.16 | $0.16 |
SpringWorks Therapeutics, Inc. Earnings Date And Information
SpringWorks Therapeutics, Inc. last posted its earnings results on Wednesday, August 6th, 2025. The company reported $-0.54 earnings per share for the quarter, topping analysts' consensus estimates of $-0.81 by $0.27. The company had revenue of 49.09 M for the quarter and had revenue of 191.59 M for the year. SpringWorks Therapeutics, Inc. has generated $-3 earnings per share over the last year ($-3.48 diluted earnings per share) and currently has a price-to-earnings ratio of -13.86. SpringWorks Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 5th, 2025 based on prior year's report dates.
SpringWorks Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 05/09/2025 | Q1 2025 | -$0.81 | -$1.11 | -0.3 | $65.70 M | $49.09 M |
| 02/20/2025 | Q4 2024 | -$0.72 | -$1.04 | -0.32 | $57.16 M | $61.55 M |
| 11/12/2024 | Q3 2024 | -$0.76 | -$0.72 | 0.04 | $53.28 M | $49.30 M |
| 08/07/2024 | Q2 2024 | -$1.12 | -$0.54 | 0.58 | $34.42 M | $59.73 M |
| 05/02/2024 | Q1 2024 | -$1.17 | -$1.18 | -0.01 | $12.07 M | $21.01 M |
| 02/27/2024 | Q4 2023 | -$1.25 | -$1.28 | -0.03 | $860.19 K | $5.45 M |
| 11/02/2023 | Q3 2023 | -$1.31 | -$1.27 | 0.04 | $200.00 K | $-11,385,000 |
| 08/02/2023 | Q2 2023 | -$1.25 | -$1.25 | 0 | N/A | $5.83 M |
| 05/03/2023 | Q1 2023 | -$1.25 | -$1.11 | 0.14 | N/A | $5.56 M |
| 02/28/2023 | Q4 2022 | -$1.21 | -$1.12 | 0.09 | N/A | $5.80 M |
| 11/03/2022 | Q3 2022 | -$1.31 | -$1.35 | -0.04 | N/A | $838.00 K |
| 08/04/2022 | Q2 2022 | -$1.26 | -$1.41 | -0.15 | N/A | $348.00 K |
| 05/05/2022 | Q1 2022 | -$1.07 | -$1.26 | -0.19 | $3.82 M | $5.00 K |
| 02/24/2022 | Q4 2021 | -$0.87 | -$1.15 | -0.28 | N/A | $0 |
| 11/04/2021 | Q3 2021 | -$0.77 | -$0.84 | -0.07 | N/A | $121.00 K |
| 08/04/2021 | Q2 2021 | -$0.70 | -$0.97 | -0.27 | N/A | $170.00 K |
| 05/05/2021 | Q1 2021 | N/A | -$0.62 | N/A | $180 | $230.00 K |
| 02/25/2021 | Q4 2020 | -$0.10 | $0.30 | 0.4 | $21.00 M | $35.00 M |
| 11/12/2020 | Q3 2020 | -$0.49 | -$0.51 | -0.02 | N/A | $0 |
| 08/12/2020 | Q2 2020 | -$0.31 | -$0.47 | -0.16 | N/A | $0 |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
SpringWorks Therapeutics, Inc. Earnings: FAQ's
SpringWorks Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 5th, 2025 based offlast year's report dates.
In the previous quarter, SpringWorks Therapeutics, Inc. (:SWTX) reported $-0.54 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.81 by $0.27.
The conference call for SpringWorks Therapeutics, Inc.'s latest earnings report can be listened to online.
The conference call transcript for SpringWorks Therapeutics, Inc.'s latest earnings report can be read online.
SpringWorks Therapeutics, Inc. (:SWTX) has a recorded annual revenue of $191.59 M.
SpringWorks Therapeutics, Inc. (:SWTX) has a recorded net income of $-258,131,000.SpringWorks Therapeutics, Inc. has generated $-3.48 earnings per share over the last four quarters.
SpringWorks Therapeutics, Inc. (:SWTX) has a price-to-earnings ratio of -13.86 and price/earnings-to-growth ratio is -6.89.